Biotech entity
Every one of those 1 sits in a single category, pharma. James McArthur is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Matt Foehr appears in 1 tracked Biotech story from March 5, 2026.
Last mentioned: Mar 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. James McArthur is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Matt Foehr appears in 1 tracked Biotech story from March 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Matt Foehr. Shared-story counts are live from our verified record — not editorial picks.
OmniAb and PepGen have released their full-year 2025 financial results, highlighting a period of operational scaling and clinical advancement. While OmniAb continues to expand its antibody discovery ecosystem, PepGen is entering a critical phase with key data readouts expected in 2026 for its neuromuscular pipeline.
Matt Foehr is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
